REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $31.63.
Several research firms have weighed in on RGNX. HC Wainwright dropped their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. The Goldman Sachs Group dropped their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, Wall Street Zen raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th.
Read Our Latest Analysis on RGNX
Insider Activity
In other news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.79% of the company's stock.
Institutional Trading of REGENXBIO
A number of hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in REGENXBIO during the first quarter worth $1,123,000. Jane Street Group LLC boosted its holdings in REGENXBIO by 151.1% during the first quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company's stock worth $2,961,000 after buying an additional 249,156 shares in the last quarter. Exome Asset Management LLC purchased a new stake in REGENXBIO during the first quarter worth $2,898,000. AQR Capital Management LLC boosted its holdings in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock worth $4,437,000 after buying an additional 594,161 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in REGENXBIO by 86.4% during the first quarter. ADAR1 Capital Management LLC now owns 350,352 shares of the biotechnology company's stock worth $2,505,000 after buying an additional 162,423 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.
REGENXBIO Stock Up 15.0%
Shares of REGENXBIO stock traded up $1.25 on Thursday, reaching $9.61. The stock had a trading volume of 1,911,387 shares, compared to its average volume of 922,954. The company has a 50 day moving average price of $8.10 and a 200 day moving average price of $7.92. REGENXBIO has a 1 year low of $5.04 and a 1 year high of $15.36. The stock has a market capitalization of $482.04 million, a P/E ratio of -1.91 and a beta of 1.09.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The firm had revenue of $89.01 million during the quarter, compared to analysts' expectations of $105.35 million. On average, analysts forecast that REGENXBIO will post -4.84 earnings per share for the current fiscal year.
REGENXBIO Company Profile
(
Get Free ReportREGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
